Document is current

Article History

Received: 23 January 2026

Accepted: 24 February 2026

First Online: 16 March 2026

Declarations

:

: Laure Gossec’s disclosures outside the submitted work include research grants from AbbVie, Lilly, Novartis and UCB; consulting fees from AbbVie, Alfasigma, Amgen, BMS, Celltrion, J&J, Lilly, MoonLake, Novartis, Oruka, Pfizer, Stada, Takeda and UCB; and non-financial support from AbbVie, Amgen, Biogen, BMS, Celltrion, J&J, Pfizer and UCB. Guillaume Bouguen reports consulting for AbbVie, Janssen, Lilly, Takeda, Celltrion and Takeda; and lecture fees from AbbVie, Sandoz, Lilly, Galapagos, Tillotts, Takeda, Janssen, Amgen and Celltrion. Azeddine Dellal reports conflicts of interest from Abbvie, Celltrion, Fresenius, Medac, Sandoz and Galapagos. Lucile Foulley, Caroline Habauzit and Salim Benkhalifa are employees of Celltrion. Hubert Marotte reports conflicts of interest from AbbVie, Celltrion Healthcare, Janssen, Lilly, Medac, Nordic Pharma, Novartis and Pfizer.

: The YU-MATTER study was conducted in compliance with the ethical standards of the 1964 Helsinki Declaration and its later amendments, deontology guidelines and Good Epidemiology Practices, and French regulations on prospective non-interventional studies. All patients were informed about the study content before enrolment and had no objections to their data being shared. The study protocol was approved on June 2, 2022, by the independent Ethics Committee of ‘Nord Ouest 3’ France (reference no. 2022-A00448-35).

: The authors thank Catherine Rees, who assisted in preparing the first draft of the manuscript on behalf of Springer Health +, Carmen Innes, BSc, CMPP, of Springer Health +, who assisted in preparing subsequent drafts, and Kate Palmer of Springer Health +, who assisted with post-submission revisions. This medical writing assistance was funded by Celltrion.